This article was originally published in The Gray Sheet
Executive SummaryPerkin-Elmer intends to sell its majority voting rights and 14.6 % capital stake in automated life sciences and diagnostics systems maker in order to focus on the genetics-based life science market, the two firms jointly announce March 18. Shares likely will be sold via public offering in Switzerland by the end of June, but PE also reserves the right to propose an opting-out clause to Tecan shareholders. An original January 1998 agreement sought to accelerate drug discovery and development through automated systems
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.